# PHERGain (NCT03161353)

> Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03161353
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: MedSIR
- Conditions: Breast Cancer
- Interventions: Perjeta; Herceptin; Docetaxel; Carboplatin; Letrozole; Tamoxifen
- Enrollment: 377
- Primary outcome: Evaluate the rate of pCR
- Primary outcome: 3-year iDFS rate

## Commentary we found

- X threads: 48
- YouTube: 6
- Podcasts: 4
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=phergain-nct03161353

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03161353", "email": "<work email>"}; the inbox owner confirms by the emailed link.